Early Results of Gene Therapy for Angelman Syndrome Look Promising

Angelman syndrome affects roughly 1 in every 20,000 children and it has no approved treatment.

Researchers recently published results of early tests of a gene therapy strategy for Angelman syndrome, a rare neurodevelopmental disorder that features poor muscle control and balance, hard-to-treat epilepsy, and intellectual disabilities.

Angelman syndrome affects roughly 1 in every 20,000 children. In United States there may be more than 15,000 people with the condition and it has no specific treatment.

The genetics of Angelman syndrome are more complicated than classic single-gene disorders such as cystic fibrosis and sickle cell anemia. Humans inherit 1 maternal and 1 paternal copy of most genes. Angelman syndrome arises in children whose maternal UBE3A copy has somehow been mutated or deleted.

For reasons that aren’t fully clear, mature neurons normally express only the maternal copy of UBE3A; the paternal copy is effectively silenced. Thus, when the maternal copy is lost, the gene’s function is absent in neurons. Because UBE3A encodes a protein that helps regulate the levels of other important proteins, its absence severely disrupts brain development.

Compounding the complexity, neurons express 2 different variants or “isoforms” of UBE3A that vary slightly in length—a short form and a long form—in a ratio of about 3 short forms for every 1 long form.

Researchers created a version of UBE3A that, when expressed by neurons, yields short and long forms of the UBE3A protein at a near-normal ratio. The scientists inserted their therapeutic UBE3A gene into a virus-based vector engineered for reliable delivery to neurons. They injected a solution of this vector into hollow spaces, called ventricles, in the brains of newborn Angelman syndrome model mice, which lack the maternal copy of the mouse Ube3a gene. Like humans with Angelman syndrome, these mice fail to express UBE3A protein in their neurons and develop motor deficits, seizures, and other neurological symptoms in the first months of life.

The scientists verified that vector-borne UBE3A became active in neurons throughout the Angelman model mouse brain just days after injection, at a level similar to that of the normal gene. This treatment restored motor skill-learning and the essential mouse behaviors of digging, burrowing, and nest-building. Untreated mice developed the usual Angelman-like impairments. The treated mice also did not become as susceptible as their untreated counterparts to experimentally induced epileptic seizures, and importantly, did not suffer any obvious negative side effects.

“This was a proof-of-concept study, but if these early results were translated to the clinic, they would represent big improvements in the quality of life for individuals with Angelman syndrome,” said study lead author Matt Judson, PhD, a research associate in the Philpot Lab at the University of North Carolina School of Medicine.

Results were published in the journal JCI Insight.

The researchers plan to further develop their strategy in additional animal models to optimize dose and delivery methods, and ultimately human clinical trials. If such a therapy were available, the researchers expect it might be able to deliver benefits to individuals of any age, but perhaps with varying benefits.

Reference

Judson MC, Shyng C, Simon JM, et al. JCI Insight. Published online October 22, 2021. doi:10.1172/jci.insight.144712.